Article

OSI, Eyetech complete $935 million merger

Melville, NY—OSI Pharmaceuticals has completed its $935 million acquisition of Eyetech Pharmaceuticals Inc. after reviewing recent data by Eyetech competitor Genentech Inc.

Melville, NY-OSI Pharmaceuticals has completed its $935 million acquisition of Eyetech Pharmaceuticals Inc. after reviewing recent data by Eyetech competitor Genentech Inc.

The deal, which was finalized Nov. 14, did not help OSI's stock price, which continued to fall from $30.35 per share on Nov. 10 to $24.62 on Nov. 18. OSI stock price, at a high of $41.03 before the Aug. 21 merger announcement, has never recovered. Meanwhile, Eyetech shares rose $1.57 to $18.19 in mid-day trading on Nov. 14.

OSI shareholders have been concerned about Genentech's ranibizumab (Lucentis) drug, which could compete with Eyetech's pegaptanib sodium (Macugen) as a treatment for age-related macular degeneration. Analysts also expressed concern about the future of OSI's relationship with Genentech, which also collaborates with OSI on erlotinib (Tarceva), a cancer drug.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
I. Paul Singh, MD, speaks about glaucoma treatment and successful ophthalmic / optometric comanagement at the 19th Annual Controversies in Modern Eye Care meeting
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
© 2025 MJH Life Sciences

All rights reserved.